|
|
 |
|
Viewing report
|
|
|
|
Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application - 2 Volume Set
John Wiley and Sons Ltd, March 2007, Pages: 1,260
Antidepressants and related psychiatric drugs are the most important prescription drugs worldwide, accounting for a market volume of 20 billion US$ per year. This handbook provides a complete and detailed overview of all currently available psychiatric drugs, covering more than 250 different compounds.
Particular features include:
- the most important information on the chemistry, pharmacology and therapeutic use of a given drug
- a special layout with margin notes and compound structures allowing for quick and easy access to the desired information
Written by drug developers from the pharmaceutical industry, novel drugs currently under development and new methods of treatment are listed side by side with classical drugs, allowing a direct comparison of traditional and innovative therapeutic approaches.
Author information
The editors all work for the Spanish-based pharmaceutical company Esteve, a world leader in neuropharmaceuticals.
Helmut Buschmann is the research director of Esteve, in charge of the discovery and development of new active substances for a variety of neurological disorders. He was formerly the head of research at Gruenenthal, a Germany-based pharma company that also specialized in neuropharmaceuticals. During his time at Gruenenthal, he published a widely acclaimed book on analgesics that pioneered the integrated approach followed also in his most recent book.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Anxiety Disorders - Viable Indication for Antipsychotics Companies
CNS Drug Discoveries: Schizophrenia Chapter
Anxiety, Phobias & Panic Disorders - 2009 Edition
Are There Changes Ahead for the Generalized Anxiety Disorder Market?
Anxiety Disorders - A Decade of Declining Revenues
Pipeline Insight: Schizophrenia
Strategic Perspectives 2001: Generalized Anxiety Disorder - Driven by Effexor and Open to Expansion
Stakeholder Insight: Anxiety Disorders - More Than Just a Comorbidity
Disease and Therapy Review: Generalized Anxiety Disorder
Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression
Pipeline and Commercial Insight: Schizophrenia - Second Generation Depots Protect Market Value
Dopamine Transporters : Chemistry, Biology, and Pharmacology
|
|
|
|
